Results 171 to 180 of about 2,976 (190)
Some of the next articles are maybe not open access.
The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer
Breast Cancer Research and Treatment, 2020The aim of this study is to evaluate the prognostic value of the Mitotic Activity Index (MAI) in combination with the human epidermal growth factor receptor (Her2) for distant metastases-free survival (DMFS) and disease-specific survival (DSS) in breast cancer and compare it with the immunohistochemically (IHC) profile types.Analyses were based on 2 ...
Jobsen, Jan J. +3 more
openaire +2 more sources
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma
Indian Journal of Surgical Oncology, 2020The process of tumorigenesis in gastric carcinoma involves multiple genetic alterations including overexpression of PD-L1, amplification of Her2neu, and mutation of p53. In the present study, the expressions of PD-L1 and Her2neu were analyzed in relation to clinicopathological parameters including p53 in gastric and gastroesophageal junction ...
Animesh Saurabh +5 more
openaire +2 more sources
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification
Journal of Clinical Pathology, 2013Aims HER2NEU gene amplification is present in the majority of invasive breast carcinomas that have HER2 protein overexpression. A subset of breast cancers harbour an increased chromosome 17 (CEP17) copy number (polysomy 17).
Maria, Orsaria +4 more
openaire +2 more sources
Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence
Clinical Oncology, 2012Determination of the risk of recurrence after local excision of ductal carcinoma in situ (DCIS) remains a challenge. Molecular profiling based on immunohistochemical staining to oestrogen receptor (ER), progesterone receptor (PR) and HER2neu improved risk prediction in invasive breast cancer, but few studies have evaluated if molecular classification ...
K, Han +9 more
openaire +2 more sources
Journal of Clinical Oncology, 2020
e16682 Background: Prognosis of Gallbladder cancer (GBC) remains unchanged over the last 20 years. Her2neu amplification is present in 17% of cases of advanced GBC. We present our experience of anti Her2 targeted therapy. Methods: This is a multicenter, prospective, observational study conducted in northern India from Sept2017-Sept2019.
Chandan Krushna Das +7 more
openaire +1 more source
e16682 Background: Prognosis of Gallbladder cancer (GBC) remains unchanged over the last 20 years. Her2neu amplification is present in 17% of cases of advanced GBC. We present our experience of anti Her2 targeted therapy. Methods: This is a multicenter, prospective, observational study conducted in northern India from Sept2017-Sept2019.
Chandan Krushna Das +7 more
openaire +1 more source
The role of determining HER2neu status in patients with gastric cancer.
Journal of Clinical Oncologye16067 Background: Over the past two decades, gastric cancer has continued to maintain a leading position in both incidence and mortality rates among all malignant neoplasms in the Republic of Kazakhstan. Recent data indicate that amplification or overexpression of the HER2 gene is detected in 7-34% of gastric cancer cases, significantly impacting ...
Rabiga Kadyrbayeva +7 more
openaire +1 more source
Harefuah, 2020
Women who present with locally advanced breast cancer that would require a mastectomy are often recommended to undergo chemotherapy prior to surgery in hopes of down-staging the tumor and allowing for breast-conserving surgery. This approach is very effective in women with triple negative and Her2neu positive locally advanced breast cancer, yet the ...
Neil S, Friedman +3 more
openaire +1 more source
Women who present with locally advanced breast cancer that would require a mastectomy are often recommended to undergo chemotherapy prior to surgery in hopes of down-staging the tumor and allowing for breast-conserving surgery. This approach is very effective in women with triple negative and Her2neu positive locally advanced breast cancer, yet the ...
Neil S, Friedman +3 more
openaire +1 more source
Journal of Clinical Oncology, 2007
21003 Background: Adjuvant trastuzumab for Her2/neu (Her2) positive breast cancer (BC) is now standard treatment. We describe hormone receptor (HR)/Her2/neu defined phenotypic BC subgroups and evaluate recurrence risk prior to widespread use of adjuvant trastuzumab.
H. G. Kaplan +2 more
openaire +1 more source
21003 Background: Adjuvant trastuzumab for Her2/neu (Her2) positive breast cancer (BC) is now standard treatment. We describe hormone receptor (HR)/Her2/neu defined phenotypic BC subgroups and evaluate recurrence risk prior to widespread use of adjuvant trastuzumab.
H. G. Kaplan +2 more
openaire +1 more source
Association between ER and HER2neu status with various sonographic findings in breast cancer
Karbala Journal of MedicineDiagnostic ultrasonography is often used as a radiological modality for assessing clinically or radiologically suspected mammary lesions based on certain radiological criteria. This study was conducted to investigate an association between breast sonographic findings and biological markers (ER and HER2\NEU). The study enrolled 100 histological
openaire +1 more source